RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Will a new recipe for a myeloma drug pass the test?
Disease control OngoingThis study compares two versions of the drug teclistamab—one made with the current process and one with a new process—in 108 people with multiple myeloma that has come back or not responded to treatment. The main goal is to see if the body absorbs and handles both versions the sa…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for blood cancer: Triple-Drug attack shows promise
Disease control OngoingThis study tests whether adding the experimental drug talquetamab to standard treatments (daratumumab and pomalidomide) helps people with multiple myeloma that has returned or stopped responding to prior therapy. About 864 adults will receive either the new combination or the usu…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New antibody therapy shows promise for Hard-to-Treat myeloma
Disease control OngoingThis study tests a drug called teclistamab in people with multiple myeloma that has come back or stopped responding to treatment. The drug is a special antibody that helps the body's immune cells find and attack cancer cells. About 194 participants will receive the drug to see ho…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for tough myeloma: first human trial of JNJ-87562761 begins
Disease control OngoingThis early-phase study tests a new drug, JNJ-87562761, in 17 people with multiple myeloma whose cancer returned or didn't respond to prior treatments. The main goals are to find a safe dose and check for side effects. Participants must have measurable disease and have tried certa…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for myeloma: adaptive trial tests smarter drug combos
Disease control OngoingThis phase II trial is testing new therapies, including the drug teclistamab, for people with multiple myeloma that has relapsed or not responded to treatment. About 300 participants will be enrolled in an adaptive platform design that allows adding new treatment arms over time. …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Multiple Myeloma Research Consortium • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New antibody therapy shows promise for Hard-to-Treat multiple myeloma
Disease control OngoingThis early-stage study tests a new drug called teclistamab in people with multiple myeloma that has returned or stopped responding to other treatments. The main goal is to find a safe dose and check for side effects. About 300 participants will receive the drug to see how well it…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for hard-to-treat myeloma: teclistamab takes on standard combos
Disease control OngoingThis study compares teclistamab (a newer immunotherapy) with two standard drug combinations (PVd or Kd) in about 614 adults whose multiple myeloma has come back or stopped responding after 1 to 3 prior treatments. The main goal is to see if teclistamab helps people live longer wi…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug SG301 tested in blood cancer patients who have run out of options
Disease control OngoingThis early-stage trial is testing a new drug called SG301 in about 61 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose to use in future studies. Researche…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New Three-Drug cocktail shows promise in Hard-to-Treat myeloma
Disease control OngoingThis phase 3 study tests whether adding the experimental drug mezigdomide to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with relapsed or refractory multiple myeloma live longer without their cancer getting worse. About 600 participants will be random…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug hope for Hard-to-Treat blood cancer
Disease control NO_LONGER_AVAILABLEThis program provides talquetamab, an experimental drug, to people with multiple myeloma that has returned or not responded to standard treatments. Talquetamab is given as an injection under the skin. The goal is to offer a potential treatment option for patients who have few alt…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for myeloma patients who have run out of options
Disease control APPROVED_FOR_MARKETINGThis program provides talquetamab, a single-drug treatment, to people with multiple myeloma that has returned or is hard to treat. Participants must have tried all other available therapies and cannot join a clinical trial. The goal is to offer a potential treatment option when n…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC